Physician profile
Laura L Cunningham
NPI 1326424904
$128,141.68
in general payments reported to CMS, 2019-2025
30 companies · $67K in 2025
The $67K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,561 · 2022: $4,588 · 2023: $21K · 2024: $27K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $28K · Travel and Lodging: $13K · Honoraria: $12K · Food and Beverage: $9,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,052.50 |
| Consulting Fee | $27,573.50 |
| Travel and Lodging | $12,747.39 |
| Honoraria | $12,250.00 |
| Food and Beverage | $9,368.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36,077.62 | 2021-2025 | Caplyta |
| Abbvie INC. | $30,091.39 | 2021-2025 | |
| Axsome Therapeutics, INC. | $25,422.24 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $19,716.85 | 2024-2025 | Cobenfy |
| Novo Nordisk INC | $9,729.48 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $3,936.23 | 2022-2025 | Quviviq, Quviviq |
| Vanda Pharmaceuticals INC. | $447.18 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $418.17 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Janssen Pharmaceuticals, INC | $291.02 | 2023-2025 | Spravato |
| Jazz Pharmaceuticals INC. | $234.76 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $218.19 | 2022-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $196.18 | 2022-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $186.27 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $186.05 | 2021-2024 | Rexulti |
| Pfizer INC. | $183.77 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $166.03 | 2022 | |
| Corium, LLC | $144.70 | 2022-2025 | Azstarys |
| Neos Therapeutics, Lp | $105.52 | 2022-2025 | Adzenys Xr-Odt, Exxua |
| Supernus Pharmaceuticals, INC. | $95.64 | 2022-2024 | Qelbree, Qelbree |
| Biogen, INC. | $44.51 | 2024-2025 | Zurzuvae |
| Alkermes, INC. | $42.10 | 2024-2025 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $39.09 | 2021 | |
| Almatica Pharma LLC | $30.15 | 2024 | Loreev Xr |
| Eisai INC. | $27.19 | 2021-2022 | |
| Lilly USA, LLC | $26.67 | 2025 | Zepbound, Mounjaro |
| Ironshore Pharmaceuticals INC. | $23.80 | 2024 | |
| Mdd US Operations, LLC | $17.22 | 2025 | Qelbree |
| Allergan, INC. | $16.53 | 2021 | |
| Dexcom, INC. | $14.44 | 2022 | |
| Bausch Health US, LLC | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.